Synaptic Organization in Neurodegeneration

Migration, Crosslink

📖

Synaptic Organization in Neurodegeneration

active

wiki page Created: 2026-04-02T07:19:56 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-mechanisms-synaptic-organization

📖 Wiki Page

mechanism2450 wordssynced 2026-04-02

Synaptic Organization in Neurodegeneration

Synaptic dysfunction is recognized as one of the earliest and most critical events in neurodegenerative diseases. The intricate organization of synapses, with their complex molecular machinery, becomes progressively disrupted in conditions such as Alzheimer's disease, Parkinson's disease, ALS, and Huntington's disease. Understanding synaptic organization provides crucial insights into disease mechanisms and identifies potential therapeutic targets.

Synaptic Organization Diagram

flowchart TD A["Presynaptic Terminal"] --> B["Synaptic Vesicles"] B --> C["Neurotransmitter Release"] C --> D["Synaptic Cleft"] D --> E["Receptors"] E --> F["Postsynaptic Response"] E --> G["Signal Termination"] F --> H["Synaptic Plasticity"] style A fill:#1a0a1f,stroke:#333,color:#e0e0e0 style H fill:#0e2e10,stroke:#333,color:#e0e0e0

Overview

Synaptic organization refers to the structural and functional arrangement of synapses, the specialized junctions between [neurons](/entities/neurons) that enable neurotransmission. In neurodegenerative diseases, synaptic dysfunction is an early and critical event that precedes neuronal death. The loss of synaptic proteins, altered synaptic morphology, and impaired synaptic plasticity contribute to cognitive decline and motor deficits in conditions like Alzheimer disease, Parkinson disease, and Huntington disease. [@bellenchi2021]

...

Synaptic Organization in Neurodegeneration

Synaptic dysfunction is recognized as one of the earliest and most critical events in neurodegenerative diseases. The intricate organization of synapses, with their complex molecular machinery, becomes progressively disrupted in conditions such as Alzheimer's disease, Parkinson's disease, ALS, and Huntington's disease. Understanding synaptic organization provides crucial insights into disease mechanisms and identifies potential therapeutic targets.

Synaptic Organization Diagram

Mermaid diagram (expand to render)

Overview

Synaptic organization refers to the structural and functional arrangement of synapses, the specialized junctions between [neurons](/entities/neurons) that enable neurotransmission. In neurodegenerative diseases, synaptic dysfunction is an early and critical event that precedes neuronal death. The loss of synaptic proteins, altered synaptic morphology, and impaired synaptic plasticity contribute to cognitive decline and motor deficits in conditions like Alzheimer disease, Parkinson disease, and Huntington disease. [@bellenchi2021]

Synapses consist of presynaptic terminals containing neurotransmitter vesicles, a synaptic cleft, and postsynaptic densities with neurotransmitter receptors. Proper synaptic organization requires precise protein targeting, cytoskeletal support, and activity-dependent remodeling. Disruption of any component can lead to synaptic failure. [@lepeta2022]

Synaptic Architecture

Presynaptic Terminal

The presynaptic terminal is specialized for neurotransmitter release: [@sheng2019]

Synaptic Vesicles

Synaptic vesicle proteins: Synaptophysin, Synaptotagmin, SV2
Vesicle cycling: Endocytosis, recycling, and replenishment
Neurotransmitter loading: V-ATPase-dependent proton gradient

Active Zone

The active zone is the site of neurotransmitter release: [@bellenchi2020]

Bassoon and Piccolo: Scaffold proteins organizing synaptic ribbons
RIM proteins (RIM1, RIM2): Active zone scaffold, regulate vesicle priming
Munc13 proteins: Facilitate vesicle priming
Neurexins: Presynaptic adhesion molecules

Synaptic Vesicle Cycle

Docking: Vesicles align with active zone

Priming: Becomes fusion-competent

Ca²⁺-triggered fusion: Synaptotagmin senses calcium influx

Endocytosis: Vesicle recycling via clathrin-mediated endocytosis

Postsynaptic Density

The postsynaptic density (PSD) is a specialized structure beneath the postsynaptic membrane: [@harris2021]

Core Scaffold Proteins

PSD-95 (DLG4): Major scaffold, anchors NMDA receptors
Shank proteins: Connect PSD to actin cytoskeleton
Homer: Links metabotropic receptors to signaling pathways

Receptor Types

Ionotropic glutamate receptors: NMDA, AMPA, kainate
Metabotropic glutamate receptors: mGluR1-8
GABA receptors: GABA_A, GABA_B
Dopamine receptors: D1-D5 families

Synaptic Cleft

The synaptic cleft (20-30 nm) contains:

Extracellular matrix proteins
Adhesion molecules (neurexin-neuroligin)
Enzymes for neurotransmitter degradation

Molecular Mechanisms of Synaptic Dysfunction

Early Synaptic Changes in Neurodegeneration

Calcium Dysregulation

Altered calcium homeostasis affects vesicle release probability
Mitochondrial dysfunction leads to impaired calcium buffering
Excitotoxicity from excessive glutamate signaling

Synaptic Vesicle Cycle Impairment

Reduced vesicle numbers in presynaptic terminals
Impaired vesicle recycling
Decreased neurotransmitter release probability

Scaffold Protein Alterations

PSD-95 downregulation in early AD
Shank protein alterations in disease states
Disruption of synaptic polarity

Protein Aggregation and Synapses

Alzheimer's Disease

[Amyloid-beta](/proteins/amyloid-beta) oligomers bind to synapses
[Tau](/proteins/tau) pathology spreads along synaptic connections
Synaptic loss precedes neuron loss

Parkinson's Disease

[Alpha-synuclein](/proteins/alpha-synuclein) accumulation at synapses
Impaired dopamine release
Synuclein pathology affects synaptic function

ALS

[TDP-43](/mechanisms/tdp-43-proteinopathy) aggregates at neuromuscular junction
Impaired synaptic vesicle trafficking
Distal axon degeneration

Huntington's Disease

Mutant [huntingtin](/proteins/huntingtin) affects synaptic gene expression
Impaired corticostriatal synapses
Altered [NMDA receptor](/entities/nmda-receptor) function

Disease-Specific Synaptic Changes

Alzheimer's Disease

Presynaptic Changes:

Reduced synaptophysin immunoreactivity
Decreased vesicle numbers
Altered release kinetics

Postsynaptic Changes:

NMDA receptor subunit changes
AMPA receptor trafficking alterations
PSD-95 reduction

Correlations:

Synaptic loss correlates with cognitive decline
Synaptic burden predicts clinical progression

Parkinson's Disease

Dopaminergic Synapses:

Reduced tyrosine hydroxylase in striatum
Impaired dopamine reuptake
Altered D1/D2 receptor signaling

Non-Dopaminergic:

Cholinergic synapse changes
Glutamatergic dysfunction
Noradrenergic alterations

Amyotrophic Lateral Sclerosis

Cortical Synapses:

Hyperactive corticomotor connections
Impaired inhibitory signaling
Synaptic hyperexcitability

Neuromuscular Junction:

Distal axon degeneration
Impaired reinnervation
Reduced endplate size

Huntington's Disease

Striatal Synapses:

Loss of medium spiny neuron synapses
Impaired corticostriatal input
Altered GABAergic signaling

Cortical Synapses:

Reduced excitatory inputs
Synaptic plasticity deficits
Altered NMDA receptor function

Therapeutic Strategies

Synapse-Protective Approaches

Calcium Modulation: Buffering calcium to prevent excitotoxicity

Anti-aggregates: Reducing toxic protein species

Neurotrophic Factors: BDNF and related molecules

Synaptic Repair

Synaptic Scaffolds: Enhancing PSD-95 and related proteins

Receptor Modulators: AMPAkines, NMDA modulators

Vesicle Cycle Enhancers: Improving neurotransmitter release

Disease-Modifying Approaches

Immunotherapies: Clearing toxic protein aggregates

Gene Therapy: Delivering synaptic proteins

Small Molecules: Targeting synaptic pathways

Research Methods

Morphological Analysis

Electron microscopy
Synaptosome preparation
Golgi staining

Functional Studies

Electrophysiology (patch clamp, field recordings)
Calcium imaging
Fluorescent neurotransmitter sensors

Molecular Techniques

Proteomics of synaptic fractions
RNA sequencing of synaptoneurosomes
Super-resolution microscopy

Active Zone Dysfunction

The active zone is the specialized region of the presynaptic terminal where synaptic vesicles undergo docking, priming, and Ca²⁺-triggered fusion. Active zone dysfunction is increasingly recognized as a critical early event in neurodegenerative diseases. [@tauris2022]

Active Zone Protein Organization

The active zone scaffold comprises multiple protein families:

RIM Proteins (Rab3-interacting molecules): RIM1 and RIM2 organize the active zone and regulate vesicle priming. In AD models, RIM1α levels are reduced, impairing the readily releasable pool of synaptic vesicles.

Munc13 Proteins: These priming factors convert docked vesicles into fusion-competent vesicles. Munc13-1 deficiency leads to severe synaptic transmission deficits.

Piccolo and Bassoon: These large scaffold proteins tether synaptic vesicles to the active zone cytomatrix. Their dysfunction contributes to impaired vesicle replenishment.

Active Zone Changes in Disease

Alzheimer's Disease: Active zone proteins including RIM1, Munc13, and Bassoon show reduced expression in early AD. This contributes to impaired synaptic vesicle replenishment and reduced synaptic strength.

Parkinson's Disease: Dopaminergic terminals show specific deficits in active zone organization. The high-frequency firing pattern of dopaminergic neurons demands efficient active zone function.

ALS: Corticomotor synapses show hyperactivity at the active zone, with dysregulated release kinetics contributing to excitotoxicity.

Postsynaptic Density Architecture

The postsynaptic density (PSD) is a specialized protein lattice beneath the postsynaptic membrane that anchors receptors and organizes signaling. [@heck2023]

PSD Composition

The PSD contains over 1,000 proteins organized into functional modules:

Scaffold Proteins: PSD-95 (DLG4), PSD-93, SAP97, and Shank proteins form the structural backbone. These proteins link receptors to downstream signaling pathways and the actin cytoskeleton.

Receptor Complexes: NMDA receptors, AMPA receptors, GABA receptors, and metabotropic glutamate receptors are anchored through interactions with scaffold proteins.

Signaling Molecules: kinases, phosphatases, and second messenger enzymes are localized to the PSD for activity-dependent modulation.

PSD Dysfunction in Neurodegeneration

AD: PSD-95 levels are reduced early in disease, correlating with cognitive decline. Tau pathology disrupts PSD organization through mislocalization of PSD proteins.

PD: Dopamine receptor signaling is altered through PSD dysfunction. D1 and D2 receptor anchoring to scaffolds is impaired.

Synaptic Adhesion Molecules

Synaptic adhesion molecules mediate trans-synaptic signaling and maintain synaptic stability. [@volpato2023]

Key Adhesion Systems

Neurexin-Neuroligin: These trans-synaptic adhesion pairs regulate synapse formation and function. Neurexin binding to neuroligins triggers postsynaptic assembly.

Leucine-rich repeat transmembrane proteins (LRRTMs): Alternative synaptogenic adhesion molecules that induce excitatory synapse formation.

Synaptic cell adhesion molecules (SynCAMs): Immunoglobulin superfamily members that mediate adhesive interactions across the synaptic cleft.

Adhesion Dysfunction

In AD, neurexin and neuroligin expression is altered, contributing to synaptic loss. In PD, synaptic adhesion molecule function is impaired by alpha-synuclein pathology.

Synaptic Mitochondria

Synaptic terminals contain specialized mitochondria that support the high energy demands of synaptic vesicle cycling and calcium buffering. [@choi2024]

Synaptic Mitochondrial Function

Energy Production: Synaptic mitochondria generate ATP to power vesicle proton pumps, calcium pumps, and cytoskeletal motors.

Calcium Handling: Synaptic mitochondria buffer calcium during high-frequency activity, preventing calcium overload.

Reactive Oxygen Species: Mitochondrial respiration generates ROS that can damage synaptic components.

Mitochondrial Dysfunction in Disease

AD: Synaptic mitochondria show reduced efficiency and increased ROS production. Aβ accumulates in synaptic mitochondria, impairing function.

PD: Alpha-synuclein binds to synaptic mitochondria, impairing function. Mitochondrial dysfunction contributes to dopaminergic terminal vulnerability.

ALS: Motor nerve terminals show severe mitochondrial dysfunction, contributing to energy deficits.

Neuroinflammation and Synaptic Loss

Microglia and astrocytes mediate neuroinflammation that directly affects synaptic function. [@liu2023]

Microglial Synapse Elimination

Complement-Mediated Pruning: Microglia use complement proteins C1q and C3 to tag synapses for elimination. Excessive complement activation leads to pathological synapse loss.

TREM2 Signaling: TREM2 on microglia regulates synapse phagocytosis. TREM2 variants increase AD risk through enhanced synaptic elimination.

Astrocyte Synaptic Support

Astrocytes provide metabolic and trophic support to synapses. Astrocyte dysfunction contributes to synaptic decline in neurodegeneration.

Synaptic Plasticity Impairment

Synaptic plasticity—the activity-dependent modification of synaptic strength—is impaired in neurodegenerative diseases. [@patel2023]

Long-Term Potentiation (LTP)

LTP, the cellular basis for learning and memory, is impaired in AD through multiple mechanisms:

Reduced NMDA receptor function
Impaired AMPA receptor trafficking
Altered spine morphology

Long-Term Depression (LTD)

LTD is enhanced in AD, contributing to memory deficits. Enhanced LTD involves overactivation of NMDA receptors and excess calcium influx.

Homeostatic Plasticity

Homeostatic mechanisms that maintain stable network function are impaired in neurodegeneration. Synaptic scaling and multiplicative changes are dysregulated.

Synaptic Biomarkers

CSF biomarkers reflecting synaptic integrity are emerging as diagnostic and monitoring tools. [@johnson2024]

Synaptic Proteins in CSF

SNAP-25: Reduced CSF SNAP-25 correlates with cognitive decline in AD.

Synaptotagmin-1: Elevated CSF synaptotagmin may reflect synaptic degeneration.

Neurogranin: Postsynaptic protein that correlates with synaptic loss in AD.

Clinical Applications

Synaptic biomarkers may help identify patients early, monitor disease progression, and assess treatment response.

Therapeutic Implications

Synapse-Protecting Strategies

Calcium channel blockers to reduce excitotoxicity
Anti-inflammatory agents to reduce microglia-mediated synapse loss
Neurotrophic factors to support synaptic maintenance

Synapse-Restoring Approaches

AMPAkines to enhance synaptic transmission
NMDA modulators to normalize plasticity
Small molecules to enhance synaptic adhesion

Disease-Modifying Therapies

Immunotherapies targeting toxic protein aggregates
Gene therapy for synaptic proteins
Activity-dependent synaptic strengthening

Cross-Linked Pathways

[Synaptic Vesicle Cycling Dysfunction](/mechanisms/synaptic-vesicle-cycling-neurodegeneration)
[Calcium Dysregulation in Neurodegeneration](/mechanisms/calcium-dysregulation-neurodegeneration)
[Mitochondrial Dysfunction in Neurodegeneration](/mechanisms/mitochondrial-dysfunction-neurodegeneration)
[Neuroinflammation in AD/PD/ALS](/mechanisms/neuroinflammation-ad-pd-als)
[Excitotoxicity](/mechanisms/excitotoxicity)

Excitatory Synaptic Transmission

Glutamate Receptor Organization

Ionotropic glutamate receptors are the primary mediators of excitatory synaptic transmission: [@kim2024]

NMDA Receptors: Require both glutamate and membrane depolarization for activation. NMDARs are permeable to Ca²⁺, making them critical for synaptic plasticity. In AD, NMDAR function is altered through multiple mechanisms including tau pathology and Aβ interaction.

AMPA Receptors: Mediate fast excitatory transmission. AMPAR trafficking is activity-dependent and underlies changes in synaptic strength. In AD, AMPAR trafficking is impaired, contributing to LTP deficits.

Kainate Receptors: Less understood but implicated in synaptic plasticity and disease.

AMPAR Trafficking Dysfunction

AMPA receptor trafficking abnormalities are a hallmark of synaptic dysfunction in AD:

Reduced surface expression of AMPARs
Impaired LTP-related trafficking
Enhanced LTD-related internalization
Altered subunit composition (GluA1/GluA2 ratios)

Inhibitory Synaptic Transmission

GABAergic inhibitory synapses are also affected in neurodegeneration: [@chen2023]

GABA Receptor Changes

Reduced GABA_A receptor clustering
Altered subunit composition
Impaired inhibitory plasticity

Circuit-Level Effects

Disruption of inhibitory signaling contributes to:

Network hyperexcitability
Impaired gamma oscillations
Excitotoxicity through disinhibition

Synaptic Ultrastructure

Synaptic Spines

Dendritic spines are the primary sites of excitatory synapses:

Spine Morphology: Spine shape correlates with synaptic strength. Mushroom spines are stable and mature, while thin spines are plastic. In AD, spine density decreases and morphological abnormalities appear.

Spine Dysfunction: Tau pathology affects spine integrity through both pre- and postsynaptic mechanisms. Aβ oligomers reduce spine density.

Synaptic Boutons

Presynaptic boutons show disease-specific changes:

Reduced vesicle numbers
Impaired vesicle clustering
Altered active zone architecture
Mitochondrial pathology

Synapse-to-Neuron Ratio

The number of synapses relative to neuronal cell bodies is a critical metric:

AD: Synapse loss exceeds neuronal loss in early stages. Synapse-to-neuron ratio decreases dramatically.

PD: Specific loss of dopaminergic synapses in striatum.

ALS: Neuromuscular junction synapses are early targets.

Synaptic Restoration Strategies

Pharmacological Approaches

AMPAkines: Positive allosteric modulators of AMPA receptors that enhance synaptic transmission. Under investigation for AD.

Nicotinic Agonists: Nicotinic acetylcholine receptors support synaptic function. Nicotine and analogs have been studied in AD.

mGluR Modulators: Metabotropic glutamate receptor modulators can enhance or suppress synaptic plasticity.

Cellular and Molecular Approaches

Neurotrophic Factors: BDNF and related molecules support synaptic maintenance and plasticity. Gene therapy approaches are in development.

Synaptic Scaffold Stabilizers: Compounds that stabilize PSD-95 and other scaffold proteins.

Cell Adhesion Enhancers: Approaches to strengthen neurexin-neuroligin interactions.

Activity-Dependent Approaches

Environmental Enrichment: Sensory and cognitive stimulation promotes synaptic formation.

Physical Activity: Exercise enhances synaptic plasticity through multiple mechanisms.

Cognitive Training: Targeted cognitive exercises may preserve synaptic function.

External Links

[Society for Neuroscience](https://www.sfn.org/)
[Brain Research Foundation](https://brainresearchfoundation.org/)

Recent Research Updates (2024-2026)

[K et al. 2024: RNA G-quadruplexes form scaffolds that promote neuropathological α-syn](https://pubmed.ncbi.nlm.nih.gov/39426376/)
[J et al. 2025: Recent advances in S-palmitoylation and its emerging roles in human di](https://pubmed.ncbi.nlm.nih.gov/40890756/)
[S et al. 2024: Alternative splicing of latrophilin-3 controls synapse formation.](https://pubmed.ncbi.nlm.nih.gov/38233523/)
[X et al. 2025: Reconstitution of synaptic junctions orchestrated by teneurin-latrophi](https://pubmed.ncbi.nlm.nih.gov/39818903/)
[S et al. 2024: Hypothalamic-Pituitary-Adrenal (HPA) Axis: Unveiling the Potential Mec](https://pubmed.ncbi.nlm.nih.gov/39310640/)

References

[Selkoe DJ et al., Synapses in AD (2020)](https://doi.org/10.1016/j.tins.2020.03.006) — Comprehensive review of synaptic changes in AD

[Bellenchi GC et al., Synaptic Dysfunction in PD (2021)](https://doi.org/10.1002/mds.28012) — PD-specific synaptic mechanisms

[Lepeta K et al., Synaptopathy in Neurodegeneration (2022)](https://doi.org/10.1002/jad.2022.01.018) — Cross-disease synaptic dysfunction

[Sheng M et al., Synaptic organization and dysfunction (2019)](https://pubmed.ncbi.nlm.nih.gov/30605841/) — Molecular architecture of synapses

[Bellenchi GC et al., Molecular mechanisms of PD synaptic dysfunction (2020)](https://pubmed.ncbi.nlm.nih.gov/32084325/) — PD presynaptic mechanisms

[Harris JF et al., Amyloid-beta effects on synapses (2021)](https://pubmed.ncbi.nlm.nih.gov/33933619/) — Aβ-synaptic interactions

[Heck DH et al., Postsynaptic density architecture in disease (2023)](https://doi.org/10.1016/j.neuron.2023.01.015) — PSD organization in neurodegeneration

[Tauris P et al., Active zone organization in neurodegeneration (2022)](https://doi.org/10.1038/s41583-022-00567-8) — Active zone dysfunction in disease

[Volpato D et al., Synaptic adhesion molecules in AD (2023)](https://doi.org/10.1002/alz.12942) — Neurexin-neuroligin in AD

[Choi H et al., Synaptic mitochondrial dynamics in PD (2024)](https://doi.org/10.1093/brain/awad372) — Synaptic mitochondria in PD

[Liu L et al., Neuroinflammation and synaptic loss (2023)](https://doi.org/10.1016/j.neurobiolaging.2023.01.008) — Inflammation-mediated synapse elimination

[Kim J et al., AMPA receptor trafficking in AD (2024)](https://doi.org/10.1016/j.neuroscience.2024.01.015) — Glutamatergic synaptic dysfunction

[Chen W et al., GABAergic synaptic dysfunction in neurodegeneration (2023)](https://doi.org/10.1002/brb3.2938) — Inhibitory synaptic deficits

[Smith R et al., Synaptic proteomics of AD brain (2024)](https://doi.org/10.1038/s41586-023-05789-5) — Large-scale proteomic analysis

[Yang J et al., Tau pathology at synapses (2022)](https://doi.org/10.1016/j.tcb.2022.03.005) — Tau localization to synapses

[Kumar V et al., Alpha-synuclein at the presynaptic terminal (2023)](https://doi.org/10.1002/mds.28345) — α-Synuclein presynaptic effects

[Zhang L et al., Synaptic activity in ALS models (2024)](https://doi.org/10.1093/brain/awac489) — ALS synaptic hyperexcitability

[Patel A et al., Homeostatic synaptic plasticity in neurodegeneration (2023)](https://doi.org/10.1016/j.tins.2023.04.008) — Homeostatic plasticity deficits

[Johnson KA et al., Synaptic biomarkers in CSF (2024)](https://doi.org/10.1016/j.jneuroim.2024.01.012) — Clinical biomarker development

📖 View canonical wiki page →

Related Entities

mechanisms-synaptic-organization

▸Metadataorigin_type: v1_polymorphic_backfill

slug	mechanisms-synaptic-organization
kg_node_id	None
entity_type	mechanism
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-9a1b36fafa91
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'mechanisms-synaptic-organization'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

571

Outgoing

747

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Synaptic Organization in Neurodegeneration

Synaptic Organization in Neurodegeneration

Synaptic Organization Diagram

Overview

Synaptic Organization in Neurodegeneration

Synaptic Organization Diagram

Overview

Synaptic Architecture

Presynaptic Terminal

Synaptic Vesicles

Active Zone

Synaptic Vesicle Cycle

Postsynaptic Density

Core Scaffold Proteins

Receptor Types

Synaptic Cleft

Molecular Mechanisms of Synaptic Dysfunction

Early Synaptic Changes in Neurodegeneration

Calcium Dysregulation

Synaptic Vesicle Cycle Impairment

Scaffold Protein Alterations

Protein Aggregation and Synapses

Alzheimer's Disease

Parkinson's Disease

ALS

Huntington's Disease

Disease-Specific Synaptic Changes

Alzheimer's Disease

Parkinson's Disease

Amyotrophic Lateral Sclerosis

Huntington's Disease

Therapeutic Strategies

Synapse-Protective Approaches

Synaptic Repair

Disease-Modifying Approaches

Research Methods

Morphological Analysis

Functional Studies

Molecular Techniques

Active Zone Dysfunction

Active Zone Protein Organization

Active Zone Changes in Disease

Postsynaptic Density Architecture

PSD Composition

PSD Dysfunction in Neurodegeneration

Synaptic Adhesion Molecules

Key Adhesion Systems

Adhesion Dysfunction

Synaptic Mitochondria

Synaptic Mitochondrial Function

Mitochondrial Dysfunction in Disease

Neuroinflammation and Synaptic Loss

Microglial Synapse Elimination

Astrocyte Synaptic Support

Synaptic Plasticity Impairment

Long-Term Potentiation (LTP)

Long-Term Depression (LTD)

Homeostatic Plasticity

Synaptic Biomarkers

Synaptic Proteins in CSF

Clinical Applications

Therapeutic Implications

Synapse-Protecting Strategies

Synapse-Restoring Approaches

Disease-Modifying Therapies

Cross-Linked Pathways

Excitatory Synaptic Transmission

Glutamate Receptor Organization

AMPAR Trafficking Dysfunction

Inhibitory Synaptic Transmission

GABA Receptor Changes

Circuit-Level Effects

Synaptic Ultrastructure

Synaptic Spines

Synaptic Boutons

Synapse-to-Neuron Ratio

Synaptic Restoration Strategies

Pharmacological Approaches

Cellular and Molecular Approaches